PBMCs from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors show variable susceptibility to HIV-1 infection: searching.

Slides:



Advertisements
Similar presentations
Dr N M Butt Consultant Haematologist
Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Ibrutinib: First-in Class Inhibitor of BTK  Forms a specific and irreversible bond with cysteine-481 in BTK  Highly potent BTK inhibition at IC 50 =
Stopping TKI treatment in CML: Who and when
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
BIOL 445 – CANCER BIOLOGY PRESENTATION
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
Gleevec vs. BMS Druker vs. Sawyers
Byrd JC et al. Proc ASCO 2011;Abstract 6508.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
THE IMMUNOPATHOGENESIS OF HIV INFECTION Lymphotropic virus.
Immune reconstitution Anjie Zhen, PhD
Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.
Christina Howlett, Pharm.D., BCOP Assistant Clinical Professor, Ernest Mario School of Pharmacy Oncology Pharmacy Specialist, Hackensack University Medical.
Ori Ben-Yehuda, MD, FACC Clinical Trials Center
HOW TO TREAT FIRST LINE FAILURE?
Soverini S et al. Proc ASH 2015;Abstract 346.
AIDS Chien-Ming Li MD, Ph.D.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Options for Treatment-Resistant or Treatment-Intolerant.
Volume 36, Issue 3, Pages (March 2012)
The Nurse View Key Insights Along the CML Continuum
ENVL-GEOL, SUST and CHEM
Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.
Cortes JE et al. Proc ASCO 2010;Abstract 6502.
Protease.
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers by Asier Sáez-Cirión, Chiraz Hamimi, Anna Bergamaschi, Annie David,
Monitoring Milestones in Patients With Chronic Myeloid Leukemia
Volume 14, Issue 9, Pages (March 2016)
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang,
Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection by Shokrollah Elahi, Toshiro Niki, Mitsuomi Hirashima,
Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade.
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
Luis A. Carvajal, Ulrich Steidl  Cell Stem Cell 
A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML by Srila Gopal, Qing Lu, Joshua.
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation by Shiguo Zhu, Prasad V. Phatarpekar,
CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE  Ke Zhang, MD, PhD, Ling.
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation by Andrew E. Schade, Gary L. Schieven, Robert.
Mak Shu Ting (18) Yip Pui Yue (29)
Experimental Hematology
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia by Edwin Bremer, Bram ten Cate, Douwe F. Samplonius,
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT by Akil A. Merchant, Aparna Jorapur, Amy McManus, Ren Liu, Valery Krasnoperov,
Volume 2, Issue 2, Pages (August 2002)
Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.
Figure 2 Effects of imatinib on components of the anticancer immunosurveillance system Figure 2 | Effects of imatinib on components of the anticancer immunosurveillance.
Volume 14, Issue 6, Pages (December 2008)
Volume 18, Issue 5, Pages (January 2017)
Volume 11, Issue 4, Pages (October 2018)
Volume 132, Issue 5, Pages (May 2007)
Branford S et al. Proc ASH 2013;Abstract 254.
Volume 36, Issue 3, Pages (March 2012)
Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.
Latent human cytomegalovirus enhances HIV-1 infection in CD34+ progenitor cells by Allen Ka Loon Cheung, Yiru Huang, Hau Yee Kwok, Min Chen, and Zhiwei.
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
Fig. 1 Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia. Effects of protein phosphatase.
Volume 21, Issue 4, Pages (April 2013)
Attacking Cancer at Its Root
The Pathway to Progress Against Chronic Myelogenous Leukemia.
PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.
by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar
Volume 18, Issue 5, Pages (January 2017)
Presentation transcript:

PBMCs from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors show variable susceptibility to HIV-1 infection: searching for the best therapeutic approach Mercedes Bermejo1, Juan Ambrosioni2, Guiomar Bautista3, Núria Climent2, Elena Mateos1, Cristina Rovira2, Rafael Duarte3, Francisco Cervantes2, Montserrat Plana2, José M. Miró2, José Alcamí1, Mayte Coiras1 1Instituto de Salud Carlos III, Madrid 2Hospital Clínic, Barcelona 3Hospital Puerta de Hierro, Madrid

CD4+ T cell activation during HIV-1 primary infection SAMHD1-phosphorylation Reverse transcription enhancement Post-integration latency P SAMHD1 SAMHD1 Massive activation of infected CD4+ T cells during acute HIV-1 infection leads to reservoir seeding and T-cell destruction. IL-2/IL-7 Resting CD4+ T cell IL-2/IL-7 IL-2/IL-7 TcR-activation Low ongoing replication Homeostatic proliferation Apoptosis Full viral replication

SAMHD1 is deactivated during T cell activation 5 days Stimuli pSAMHD1 CD4+ T cells Coiras et al., Cell Rep. 2016 Mar 8;14(9):2100-7 PHA and anti-CD3 induce SAMHD1 phosphorylation at T592 IL-2 and IL-7 sustain SAMHD1 phosphorylation

Tyrosine kinase p56Lck is essential for T cell activation HIV-1 replication Bermejo et al., Biochem Pharmacol. 2016;106:30-45 Wang et al., Front Immunol. 2012 Jul 11;3:197

Tyrosine kinase inhibitors are used in clinic for treating chronic myeloid leukemia Bosutinib Bcr-Abl: quimeric fusion protein with uncontrolled tyrosine kinase activity

Tyrosine kinase inhibitors are used in clinic for treating chronic myeloid leukemia First TKI against BCR-ABL introduced in clinical practice: Imatinib Second generation TKIs: Third generation TKIs: Ponatinib Nilotinib Dasatinib Bosutinib Dasatinib is a multi-targeted inhibitor of Bcr-Abl and Src family kinases that exclusively binds the active conformation of Abl kinase, contrary to most TKIs

Tyrosine kinase inhibitors interfere with HIV-1 replication in vitro PBMCs from healthy donors Imatinib Nilotinib Dasatinib 8.2 M 9.2 M 16.3 nM IC50 (nM) 8259 CC50 (nM) > 20000 R2 0.9813 - SI > 2.42 IC50 (nM) 9280 CC50 (nM) > 30000 R2 0.9608 0.8962 SI > 3.23 IC50 (nM) 16.34 CC50 (nM) > 10000 R2 0.9532 - SI > 612 Bosutinib Ponatinib Dasatinib and Ponatinib were the most potent inhibitors of HIV-1 replication (nM concentration) 618 nM 145 nM IC50 (nM) 618.4 CC50 (nM) 1031 R2 0.9531 0.9917 SI 1.66 IC50 (nM) 145.6 CC50 (nM)  10000 R2 0.9541 0.9866 SI  68.68

Tyrosine kinase inhibitors interfere with SAMHD1 phosphorylation in vitro PBMCs from healthy donors Imatinib and nilotinib did not interfere with SAMHD1 phosphorylation induced by CD3/CD28/IL-2 All ITKs interfere with SAMHD1 phosphorylation induced by IL-2 Imatinib did not interfere with SAMHD1 phosphorylation induced by IL-7

Effect of TKIs on HIV-1 co-receptors expression PBMCs Flow cytometry: CXCR4 and CCR5 3 days + CD3/CD28/IL-2

between IC50 in vitro and Cmax in vivo Correlation of TKIs between IC50 in vitro and Cmax in vivo Imatinib Nilotinib Dasatinib Bosutinib Ponatinib IC50 8.2 M (4.07 g/ml) 9.2 M (4.91 µg/ml) 16.3 nM (8.26 ng/ml) 618 nM (327.28 ng/ml) 145 nM (77.46 ng/ml) Cmax 2.35 µg/ml (400 mg once in healthy adults 1.59 µg/ml (400 mg twice in CML patients) 41.52 ng/ml (50 mg once in healthy adults) 120-141 ng/ml (600 mg once in CML patients and healthy adults, respectively) 54.7 ng/ml (45 mg once in healthy adults) IC50/Cmax 1.7 3.0 0.2 2.3 1.4 Selectivity index > 2.42 > 3.23 > 612 1.66  68.68 Dasatinib would need lower concentration to interfere with HIV-1 replication than for the treatment of CML Similar concentration of imatinib and ponatinib would be needed

PBMCs from CML patients on treatment with TKIs No samples Age at sampling (years) Time of treatment (years) Dose of TKI (mg/d) Lymphocyte count (106/ml) Imatinib 15 67 4.8 392 (400) 1788 Nilotinib 11 51 4.4 585 (600) 2161 Dasatinib 52 2.5 96 (100) 2108 Bosutinib 4 2 250 (200) 1903 Ponatinib 1 70 5 15 (15) 1400 Parameters: Negative for HIV-1 infection Hematological remission Cytogenetic remission CML chronic stage

PBMCs from CML patients on treatment with TKIs Proviral integration Viral proteins 48 hours 5 days + CD3/CD28/IL-2 + NL4-3_Renilla Proviral DNA Viral protein expression

PBMCs from CML patients on treatment with TKIs Proviral integration Viral proteins 48 hours 5 days + CD3/CD28/IL-2 + NL4-3_Renilla 5 hours (RT)

SAMHD1 phosphorylation in PBMCs from CML patients on treatment with TKIs PBMCs PHA/IL-2 5 days Analysis of pSAMHD1 CD4+ T cells Dasatinib (n=6); Imatinib (n=5); Nilotinib (n=5), Bosutinib (n=2), Ponatinib (n=1), Healthy (n=6)

Effect of TKIs on T cell proliferation + CD3/CD28/IL-2 3d PBMCs CFSE, flow cytometry

Effect of TKIs on T cell proliferation + stimuli PBMCs CFSE Dasatinib and ponatinib interfered with T cells proliferation induced by any stimuli

Mechanisms of inhibition of HIV-1 cycle by TKIs TKIs specifically block SAMHD1 phosphorylation and inhibits viral reverse transcription Through inhibition of T-cell activation, TKIs inhibit full viral replication Reservoir expansion is blocked by interfering with the homeostatic proliferation of latently infected T cells Coiras et al., Opin Drug Saf. 2017 May;16(5):547-559

Conclusions In vivo treatment with TKIs preserves SAMHD1-mediated restriction to HIV-1 infection through the inhibition of its phosphorylation. As a consequence, PBMCs from CML patients were refractory to HIV-1 reverse transcription and, consequently, to proviral integration. Dasatinib is the most potent TKI against HIV-1 replication, closely followed by ponatinib. Dasatinib showed the best therapeutic index, with IC50 lower than Cmax for CML treatment. Treatment with dasatinib or ponatinib interfered with CD4+ T cell activation and proliferation induced by several physiological stimuli. Dasatinib could control the size of the reservoir by interfering with its formation and with the replenishment induced by homeostatic proliferation.

Research team AIDS Immunopathology, National Center of Microbiología, Instituto Carlos III. Madrid Pepe Alcamí The patients Mayte Coiras Elena Mateos Sara Rodríguez-Mora Mercedes Bermejo MªRosa López-Huertas